Cancer Research Targets  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, J.-H.
Right arrow Articles by Kim, D.-G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, J.-H.
Right arrow Articles by Kim, D.-G.
[Cancer Research 65, 6312-6320, July 15, 2005]
© 2005 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

Susceptibility of Cholangiocarcinoma Cells to Parthenolide-Induced Apoptosis

Jong-Hyun Kim1, Lan Liu1, Seung-Ok Lee1, Yong-Tae Kim2, Kyung-Ran You1 and Dae-Ghon Kim1

1 Division of GI and Hepatology, Department of Internal Medicine, Institute for Molecular Biology and Genetics, Chonbuk National University Medical School and Hospital, Jeonju, Jeonbuk and 2 Department of Internal Medicine, Seoul National University School of Medicine, Seoul, Republic of Korea

Requests for reprints: Dae-Ghon Kim, Division of GI and Hepatology, Chonbuk National University Medical School and Hospital, 634-18 Keumam-dong, Dukjin-ku, Jeonju, Jeonbuk 561-712, Republic of Korea. Phone: 82-63-250-1681; Fax: 82-63-254-1609; E-mail: daeghon{at}moak.chonbuk.ac.kr.

Cholangiocarcinomas are intrahepatic bile duct carcinomas that are known to have a poor prognosis. Sesquiterpene lactone parthenolide, which is the principal active component in medicinal plants, has been used to treat tumors. Parthenolide effectively induced apoptosis in all four cholangiocarcinoma cell lines in a dose-dependent manner. However, the sarcomatous SCK cells were more sensitive to parthenolide than the other adenomatous cholangiocarcinoma cells. Therefore, this study investigated whether or not the expression of p53, the Fas/Fas ligand (FasL), Bcl-2/Bcl-XL determines the enhanced drug susceptibility of SCK cells. The results showed that Bcl-2 family molecules, such as Bid, Bak, and Bax, are involved in the parthenolide-induced apoptosis and that the defective expression of Bcl-XL might contribute to the higher parthenolide sensitivity in the SCK cells than in the other adenomatous cholangiocarcinoma cells. SCK cells, which stably express Bcl-XL, were resistant to parthenolide, whereas Bcl-XL-positive Choi-CK cells transfected with the antisense Bcl-XL showed a higher parthenolide sensitivity than the vector control cells. Molecular dissection revealed that Bcl-XL inhibited the translocation of Bax to the mitochondria, decreased the generation of intracellular reactive oxygen species, reduced the mitochondrial transmembrane potential ({Delta}{Psi}m), decreased the release of cytochrome c, decreased the cleavage of poly(ADP-ribose) polymerase, and eventually inhibited apoptotic cell death. These results suggest that parthenolide effectively induces oxidative stress-mediated apoptosis, and that the susceptibility to parthenolide in cholangiocarcinoma cells might be modulated by Bcl-XL expression in association with Bax translocation to the mitochondria.




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
C. Riganti, S. Doublier, C. Costamagna, E. Aldieri, G. Pescarmona, D. Ghigo, and A. Bosia
Activation of Nuclear Factor-{kappa}B Pathway by Simvastatin and RhoA Silencing Increases Doxorubicin Cytotoxicity in Human Colon Cancer HT29 Cells
Mol. Pharmacol., August 1, 2008; 74(2): 476 - 484.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Suvannasankha, C. D. Crean, R. Shanmugam, S. S. Farag, R. Abonour, H. S. Boswell, and H. Nakshatri
Antimyeloma Effects of a Sesquiterpene Lactone Parthenolide
Clin. Cancer Res., March 15, 2008; 14(6): 1814 - 1822.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Sun, D. K. St. Clair, F. Fang, G. W. Warren, V. M. Rangnekar, P. A. Crooks, and W. H. St. Clair
The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-{kappa}B inhibition and enhanced by the presence of PTEN
Mol. Cancer Ther., September 1, 2007; 6(9): 2477 - 2486.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Fonrose, F. Ausseil, E. Soleilhac, V. Masson, B. David, I. Pouny, J.-C. Cintrat, B. Rousseau, C. Barette, G. Massiot, et al.
Parthenolide Inhibits Tubulin Carboxypeptidase Activity
Cancer Res., April 1, 2007; 67(7): 3371 - 3378.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Kishida, H. Yoshikawa, and A. Myoui
Parthenolide, a Natural Inhibitor of Nuclear Factor-{kappa}B, Inhibits Lung Colonization of Murine Osteosarcoma Cells
Clin. Cancer Res., January 1, 2007; 13(1): 59 - 67.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.